# A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

> **NCT07470983** · PHASE2 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Primary Aldosteronism

## Interventions

- **DRUG:** HRS-1780 Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07470983
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-23
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07470983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07470983, "A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07470983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*